Clinicopathological correlations of Bcl-xL and Bax expression in differentiated thyroid carcinoma

Clinical Endocrinology

Volumn 68, Issue 2, 2008, Pages 190-197

  Martínez Brocca, M Asunción ^a   Castilla, Carolina ^a   Navarro, Elena ^a   Amaya, M José ^a   Travado, Paulino ^a   Japón, Miguel A ^a   Sáez, Carmen ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL XL;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; WESTERN BLOTTING;

BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; HUMANS; IMMUNOHISTOCHEMISTRY; THYROID DISEASES; THYROID GLAND; THYROID NEOPLASMS;

EID: 38049175034     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03018.x     Document Type: Article

References (41)

1. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J. Thun, M.J. (2005) Cancer statistics. CA: A Cancer Journal for Clinicians, 55, 10 30.
2. Vini, L. Harmer, C. (2002) Management of thyroid cancer. Lancet Oncology, 3, 407 414.
3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Available from URL : http://www.seer.cancer.gov [Accessed November 2006].
4. Hundahl, S.A., Fleming, I.D., Frengen, A.M. Menck, H.R. (1998) A national cancer data base report on 53856 cases of thyroid carcinoma treated in the US 1985-95. Cancer, 83, 2638 2648.
5. Mazzaferri, E.L. Jhiang, S.M. (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine, 97, 418 428.
6. Wreesmann, V.B., Sieczka, E.M., Socci, N.D., Hezel, M., Belbin, T.J., Childs, G., Patel, S.G., Patel, K.N., Tallini, G., Prystowsky, M., Shaha, A.R., Kraus, D., Shah, J.P., Rao, P.H., Ghossein, R. Singh, B. (2004) Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Research, 64, 3780 3789.
7. Garcia-Rostan, G., Zhao, H., Camp, R.L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M.L., Costa, J. Tallini, G. (2003) ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology, 21, 3226 3235.
8. Brecelj, E., Frkovic, G.S., Auersperg, M. Bracko, M. (2005) Prognostic value of E-cadherin expression in thyroid follicular carcinoma. European Journal of Surgical Oncology, 31, 544 548.
9. Zou, M., Famulski, K.S., Parhar, R.S., Baitei, E., Al-Mohanna, F.A., Farid, N.R. Shi, Y. (2004) Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 89, 6146 6154.
10. Weber, K.B., Shroyer, K.R., Heinz, D.E., Nawaz, S., Said, M.S. Haugen, B.R. (2004) The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. American Journal of Clinical Pathology, 122, 524 531.
11. Khoo, M.L., Beasley, N.J., Ezzat, S., Freeman, J.L. Asa, S.L. (2002) Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 87, 1814 1818.
12. Sáez, C., Martínez-Brocca, M.A., Castilla, C., Soto, A., Navarro, E., Tortolero, M., Pintor-Toro, J.A. Japón, M.A. (2006) Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 91, 1404 1409.
13. Xing, M., Westra, W.H., Tufano, R.P., Cohen, Y., Rosenbaum, E., Rhoden, K.J., Carson, K.A., Vasko, V., Larin, A., Tallini, G., Tolaney, S., Holt, E.H., Hui, P., Umbricht, C.B., Basaria, S., Ewertz, M., Tufaro, A.P., Califano, J.A., Ringel, M.D., Zeiger, M.A., Sidransky, D. Ladenson, P.W. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 90, 6373 6379.
14. Jurgensmeier, J.M., Xie, Z., Deveraux, Q., Ellerby, L., Bredsen, D. Reed, J.C. (1998) Bax directly induces release of cytochrome c from isolated mitochondria. Proceedings of the National Academy of Sciences of the United States of America, 95, 4997 5002.
15. Adams, J.M. Cory, S. (1998) The Bcl-2 protein family: arbiters of cell survival. Science, 281, 1322 1326.
16. Cartron, P.F., Juin, P., Oliver, L., Martin, S., Meflah, K. Vallette, F.M. (2003) Nonredundant role of Bax and Bak in Bid-mediated apoptosis. Molecular and Cellular Biology, 23, 4701 4712.
17. Zhang, L., Yu, J., Park, B.H., Kinzler, K.W. Vogelstein, B. (2000) Role of BAX in the apoptotic response to anticancer agents. Science, 290, 989 992.
18. Li, X., Marani, M., Mannucci, R., Kinsey, B., Andriani, F., Nicoletti, I., Denner, L. Marcelli, M. (2001) Overexpression of BCL-XL underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Research, 61, 1699 1706.
19. Kojima, H., Endo, K., Moriyama, H., Tanaka, Y., Alnemri, E.S., Slapak, C.A., Teicher, B., Kufe, D. Datta, R. (1998) Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. Journal of Biological Chemistry, 237, 16647 16650.
20. Krajewska, M., Moss, S.K., Krajewski, S., Song, K., Holt, P.R. Reed, J.C. (1996) Elevated expression of Bcl-x and reduced Bak in primary colorectal adenocarcinomas. Cancer Research, 56, 2422 2427.
21. Krajewska, M., Krajewski, S., Epstein, J.I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S. Reed, J.C. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. American Journal of Pathology, 148, 1567 1576.
22. Tu, Y., Renner, F., Xu, A., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J.C. Lichtenstein, A. (1998) Bcl-x expression in multiple myeloma: possible indicator of chemoresistance. Cancer Research, 58, 256 262.
23. Branet, F., Brousset, P., Krajewski, S., Schlaifer, D., Selves, J., Reed, J.C. Caron, P. (1996) Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. Journal of Clinical Endocrinology and Metabolism, 81, 2726 2730.
24. Manetto, V., Lorenzini, R., Cordon-Cardo, C., Krajewski, S., Rosai, J., Reed, J.C. Eusebi, V. (1997) Bcl-2 and Bax expression in thyroid tumors. Virchows Archiv, 430, 125 130.
25. Stassi, G., Todaro, M., Zerilli, M., Ricci-Vitiani, L., Di Liberto, D., Patti, M., Florena, A., Di Gaudio, F., Di Gesú, G. De Maria, R. (2003) Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of nterleukin-4 and interleukin-10. Cancer Research, 63, 6784 6790.
26. Hermann, S., Sturm, I., Mrozek, A., Klosterhalfen, B., Hauptmann, S., Dörken, B. Daniel, P.T. (2001) Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type p53 is associated with a high Bax and p21 expression in thyroid carcinoma. International Journal of Cancer, 92, 805 811.
27. Sobin, L.H. Wittekind, C. (2002) TNM Classification of Malignant Tumors, 6th edn. Wiley-Liss, New York, 52 56.
28. Thyroid Carcinoma Task Force 2001) AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocrine Practice, 7, 202 220.
29. Kloos, R.T. (2005) Papillary thyroid cancer: medical management and follow-up. Current Treatment Options in Oncology, 6, 323 338.
30. Mazzaferri, E.L., Robbins, R.J., Spencer, C.A., Braverman, L.E., Pacini, F., Wartofsky, L., Haugen, B.R., Sherman, S.I., Cooper, D.S., Braunstein, G.D., Lee, S., Davies, T.F., Arafah, B.M., Ladenson, P.W. Pinchera, A. (2003) A consensus report of the role of thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 88, 1433 1441.
31. Schlumberger, M., Berg, G., Cohen, O., Duntas, L., Jamar, F., Jarzab, B., Limbert, E., Lind, P., Pacini, F., Reiners, C., Sanchez Franco, F., Toft, A. Wiersinga, W.M. (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. European Journal of Endocrinology, 50, 105 112.
32. Huang, Z. (2000) Bcl-2 family proteins as targets for anticancer drug design. Oncogene, 19, 6627 6631.
33. Lebedeva, I., Rando, R., Ojwang, J., Cossum, P. Stein, C.A. (2000) Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Research, 60, 6052 6060.
34. Liu, Q.Y. Stein, C.A. (1997) Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. Clinical Cancer Research, 3, 2039 2046.
35. Takehara, T., Liu, X., Fujimoto, J., Friedman, S.L. Takahashi, H. (2001) Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology, 34, 55 61.
36. Castilla, C., Congregado, B., Chinchon, D., Torrubia, F.J., Japon, M.A. Saez, C. (2006) Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology, 147, 4960 4967.
37. Letsas, K.P., Frangou-Lazaridis, M., Skyrlas, A., Tsatsoulis, A. Malamou-Mitsi, V. (2005) Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions. Pathology International, 55, 694 702.
38. Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T. Yuan, J. (2001) Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nature Cell Biology, 3, 173 182.
39. Ming, L., Wang, P. Bank, A., Yu, J. Zhang, L. (2006) PUMA dissociates Bax and BCL-XL to induce apoptosis in colon cancer cells. Journal of Biological Chemistry, 281, 16034 16042.
40. Zi, X. Simoneau, A.R. (2005) Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Research, 65, 3479 3486.
41. Upreti, M., Lyle, C.S., Du Skaug, B., L. Chambers, T.C. (2006) Vinblastine-induced apoptosis is mediated by discrete alterations in subcellular location, oligomeric structure, and activation status of specific Bcl-2 family members. Journal of Biological Chemistry, 281, 15941 15950.